THE Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University has announced the licensing of a lymphatic drug targeting technology platform to Boston, USA-based PureTech Health, a clinical-stage biopharmaceutical company.
Named 'Glyph', the platform is aimed at harnessing the biology of the human lymphatic system to develop novel therapeutics, including those that selectively target certain lymph nodes.
Glyph has potential for the development of new medicines that are both more potent and less toxic to the liver, holding promise for new treatments for a range of conditions from cancer to autoimmune disease.
The technology has been developed by Professor Chris Porter's group at the ARC Centre of Excellence for Bio-Nano Science and Technology at MIPS, with inventors including Tim Quach, Sifei Han, Luojuan Hu, Natalie Trevaskis, Jamie Simpson and Chris Porter.
A new PureTech Health offshoot called Glyph Biosciences will progress the system towards clinical trial in collaboration with the Monash laboratory.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Aug 17